Quest Diagnostics Inc (NYSE:DGX) EVP J. E. Davis sold 494 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $102.74, for a total value of $50,753.56. Following the transaction, the executive vice president now owns 41,691 shares of the company’s stock, valued at $4,283,333.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of Quest Diagnostics Inc (NYSE:DGX) traded up $0.73 during trading hours on Tuesday, hitting $104.79. The stock had a trading volume of 1,540,000 shares, compared to its average volume of 1,080,000. Quest Diagnostics Inc has a 52 week low of $90.10 and a 52 week high of $112.96. The firm has a market capitalization of $14,280.00, a price-to-earnings ratio of 22.15, a PEG ratio of 1.84 and a beta of 0.67. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.15 and a current ratio of 1.24.
Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, February 1st. The medical research company reported $1.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.37 by $0.03. Quest Diagnostics had a return on equity of 15.41% and a net margin of 10.00%. The company had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. During the same period last year, the company posted $1.31 earnings per share. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. analysts predict that Quest Diagnostics Inc will post 6.59 EPS for the current fiscal year.
Several research firms have issued reports on DGX. Zacks Investment Research upgraded Quest Diagnostics from a “hold” rating to a “buy” rating and set a $115.00 price objective for the company in a research note on Tuesday, February 6th. Evercore ISI began coverage on Quest Diagnostics in a research note on Thursday, January 4th. They set an “in-line” rating and a $103.00 price objective for the company. Piper Jaffray Companies reiterated a “hold” rating and set a $110.00 price objective on shares of Quest Diagnostics in a research note on Thursday, February 1st. Mizuho set a $113.00 price objective on Quest Diagnostics and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Finally, Jefferies Group set a $98.00 price objective on Quest Diagnostics and gave the stock a “hold” rating in a research note on Saturday, November 25th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and nine have given a buy rating to the company. Quest Diagnostics presently has a consensus rating of “Hold” and an average price target of $107.40.
A number of institutional investors have recently bought and sold shares of the stock. GHP Investment Advisors Inc. boosted its holdings in Quest Diagnostics by 5.3% in the fourth quarter. GHP Investment Advisors Inc. now owns 10,131 shares of the medical research company’s stock valued at $998,000 after acquiring an additional 509 shares during the last quarter. Conning Inc. boosted its holdings in Quest Diagnostics by 5.1% in the fourth quarter. Conning Inc. now owns 10,583 shares of the medical research company’s stock valued at $1,042,000 after acquiring an additional 510 shares during the last quarter. AMG Funds LLC boosted its holdings in Quest Diagnostics by 4.3% in the fourth quarter. AMG Funds LLC now owns 12,437 shares of the medical research company’s stock valued at $1,225,000 after acquiring an additional 516 shares during the last quarter. US Bancorp DE boosted its holdings in Quest Diagnostics by 3.0% in the fourth quarter. US Bancorp DE now owns 18,451 shares of the medical research company’s stock valued at $1,817,000 after acquiring an additional 531 shares during the last quarter. Finally, Norinchukin Bank The boosted its holdings in Quest Diagnostics by 2.1% in the third quarter. Norinchukin Bank The now owns 27,086 shares of the medical research company’s stock valued at $2,536,000 after acquiring an additional 549 shares during the last quarter. Institutional investors and hedge funds own 88.67% of the company’s stock.
WARNING: This report was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3226504/quest-diagnostics-inc-dgx-evp-sells-50753-56-in-stock.html.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.